Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael W Pride

Showing results (1-10 of 41) with videos related to

Pageof 5
Sort By:
Interdisciplinary Topics in Gerontology and Geriatrics|April 20, 2020
Vaccination against Nosocomial Infections in Elderly AdultsAnnaliesa S Anderson, Ingrid L Scully, Michael W Pride, et al.
Vaccine|March 20, 2016
A phase 1, placebo-controlled, randomized study of the safety, tolerability, and immunogenicity of a Clostridium difficile vaccine administered with or without aluminum hydroxide in healthy adultsEric Sheldon, Nicholas Kitchin, Yahong Peng, et al.
The Journal of Infectious Diseases|October 5, 2013
Distribution of 13-valent pneumococcal conjugate vaccine Streptococcus pneumoniae serotypes in US adults aged ≥50 years with community-acquired pneumoniaRobert L Sherwin, Sharon Gray, Ronika Alexander, et al.
Vaccine|April 10, 2019
A phase 1 randomized study assessing safety and immunogenicity of two 3-dose regimens of a Clostridium difficile vaccine in healthy older Japanese adultsMegumi Inoue, Takuma Yonemura, Richard de Solom, et al.
Vaccine|September 6, 2021
Safety and immunogenicity of different Clostridioides (Clostridium) difficile vaccine formulations in two early phase randomized studies of healthy adults aged 50-85 yearsJody Lawrence, Nicholas Kitchin, Annaliesa S Anderson, et al.
The Journal of Infectious Diseases|September 4, 2023
Multicountry Review of Streptococcus pneumoniae Serotype Distribution Among Adults With Community-Acquired PneumoniaLindsay R Grant, Elizabeth Begier, Christian Theilacker, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|May 25, 2019
A Phase 2 Study Evaluating the Safety, Tolerability, and Immunogenicity of Two 3-Dose Regimens of a Clostridium difficile Vaccine in Healthy US Adults Aged 65 to 85 YearsNicholas Kitchin, Shon A Remich, James Peterson, et al.
Cellular Immunology|June 10, 2006
Epitope mapping of full-length glycoprotein D from HSV-2 reveals a novel CD4+ CTL epitope located at the transmembrane-cytoplasmic junctionDavid Cooper, Joseph C Mester, Min Guo, et al.
Clinical and Vaccine Immunology : CVI|May 2, 2008
Correlation of cellular immune responses with protection against culture-confirmed influenza virus in young childrenBruce D Forrest, Michael W Pride, Andrew J Dunning, et al.
The Journal of Infectious Diseases|August 2, 2023
A Phase 2 Extension Study Evaluating the Immunogenicity, Safety, and Tolerability of 3 or 4 Doses of a Clostridioides difficile Vaccine in Healthy US Adults Aged 65 to 85 YearsShon Remich, Nicholas Kitchin, James Peterson, et al.
Pageof 5

Showing results (1-10 of 41) with videos related to

Sort By:
Pageof 5
Interdisciplinary Topics in Gerontology and Geriatrics|April 20, 2020
Vaccination against Nosocomial Infections in Elderly AdultsAnnaliesa S Anderson, Ingrid L Scully, Michael W Pride, et al.
Vaccine|March 20, 2016
A phase 1, placebo-controlled, randomized study of the safety, tolerability, and immunogenicity of a Clostridium difficile vaccine administered with or without aluminum hydroxide in healthy adultsEric Sheldon, Nicholas Kitchin, Yahong Peng, et al.
The Journal of Infectious Diseases|October 5, 2013
Distribution of 13-valent pneumococcal conjugate vaccine Streptococcus pneumoniae serotypes in US adults aged ≥50 years with community-acquired pneumoniaRobert L Sherwin, Sharon Gray, Ronika Alexander, et al.
Vaccine|April 10, 2019
A phase 1 randomized study assessing safety and immunogenicity of two 3-dose regimens of a Clostridium difficile vaccine in healthy older Japanese adultsMegumi Inoue, Takuma Yonemura, Richard de Solom, et al.
Vaccine|September 6, 2021
Safety and immunogenicity of different Clostridioides (Clostridium) difficile vaccine formulations in two early phase randomized studies of healthy adults aged 50-85 yearsJody Lawrence, Nicholas Kitchin, Annaliesa S Anderson, et al.
The Journal of Infectious Diseases|September 4, 2023
Multicountry Review of Streptococcus pneumoniae Serotype Distribution Among Adults With Community-Acquired PneumoniaLindsay R Grant, Elizabeth Begier, Christian Theilacker, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|May 25, 2019
A Phase 2 Study Evaluating the Safety, Tolerability, and Immunogenicity of Two 3-Dose Regimens of a Clostridium difficile Vaccine in Healthy US Adults Aged 65 to 85 YearsNicholas Kitchin, Shon A Remich, James Peterson, et al.
Cellular Immunology|June 10, 2006
Epitope mapping of full-length glycoprotein D from HSV-2 reveals a novel CD4+ CTL epitope located at the transmembrane-cytoplasmic junctionDavid Cooper, Joseph C Mester, Min Guo, et al.
Clinical and Vaccine Immunology : CVI|May 2, 2008
Correlation of cellular immune responses with protection against culture-confirmed influenza virus in young childrenBruce D Forrest, Michael W Pride, Andrew J Dunning, et al.
The Journal of Infectious Diseases|August 2, 2023
A Phase 2 Extension Study Evaluating the Immunogenicity, Safety, and Tolerability of 3 or 4 Doses of a Clostridioides difficile Vaccine in Healthy US Adults Aged 65 to 85 YearsShon Remich, Nicholas Kitchin, James Peterson, et al.
Pageof 5